Published in Anal Bioanal Chem on April 21, 2010
The proteoglycan bikunin has a defined sequence. Nat Chem Biol (2011) 2.14
E. coli K5 fermentation and the preparation of heparosan, a bioengineered heparin precursor. Biotechnol Bioeng (2010) 1.65
Control of the heparosan N-deacetylation leads to an improved bioengineered heparin. Appl Microbiol Biotechnol (2011) 1.33
Heparin mapping using heparin lyases and the generation of a novel low molecular weight heparin. J Med Chem (2010) 1.24
Masquerading microbial pathogens: capsular polysaccharides mimic host-tissue molecules. FEMS Microbiol Rev (2014) 1.05
Proteoglycan sequence. Mol Biosyst (2012) 0.98
Escherichia coli K5 heparosan fermentation and improvement by genetic engineering. Bioeng Bugs (2011) 0.97
Glycosaminoglycan characterization by electrospray ionization mass spectrometry including fourier transform mass spectrometry. Methods Enzymol (2010) 0.96
Sequence analysis and domain motifs in the porcine skin decorin glycosaminoglycan chain. J Biol Chem (2013) 0.91
Domain structure elucidation of human decorin glycosaminoglycans. Biochem J (2010) 0.91
Controlled Photochemical Depolymerization of K5 Heparosan, a Bioengineered Heparin Precursor. Carbohydr Polym (2011) 0.85
Draft Genome Sequence of Escherichia coli Strain Nissle 1917 (Serovar O6:K5:H1). Genome Announc (2013) 0.83
Engineered heparins as new anticoagulant drugs. Bioeng Transl Med (2016) 0.81
Draft Genome Sequence of Escherichia coli Strain ATCC 23506 (Serovar O10:K5:H4). Genome Announc (2013) 0.77
Cyclic AMP (cAMP) Receptor Protein-cAMP Complex Regulates Heparosan Production in Escherichia coli Strain Nissle 1917. Appl Environ Microbiol (2015) 0.77
Molecular Mass Characterization of Glycosaminoglycans with Different Degrees of Sulfation in Bioengineered Heparin Process by Size Exclusion Chromatography. Curr Anal Chem (2012) 0.76
Heparin-protein interactions. Angew Chem Int Ed Engl (2002) 7.27
Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl J Med (2008) 7.05
Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events. Nat Biotechnol (2008) 4.46
2003 Claude S. Hudson Award address in carbohydrate chemistry. Heparin: structure and activity. J Med Chem (2003) 3.71
The structure of the capsular polysaccharide (K5 antigen) of urinary-tract-infective Escherichia coli 010:K5:H4. A polymer similar to desulfo-heparin. Eur J Biochem (1981) 2.84
Lessons learned from the contamination of heparin. Nat Prod Rep (2009) 2.81
Structural insights into biological roles of protein-glycosaminoglycan interactions. Chem Biol (2005) 2.67
Generation of "neoheparin" from E. coli K5 capsular polysaccharide. J Med Chem (2005) 2.03
Solution structures of chemoenzymatically synthesized heparin and its precursors. J Am Chem Soc (2008) 2.02
Gradient polyacrylamide gel electrophoresis for determination of molecular weights of heparin preparations and low-molecular-weight heparin derivatives. J Pharm Sci (1992) 1.80
Heparin-binding domains in vascular biology. Arterioscler Thromb Vasc Biol (2004) 1.71
Design of biologically active heparan sulfate and heparin using an enzyme-based approach. Nat Prod Rep (2009) 1.39
Orthogonal analytical approaches to detect potential contaminants in heparin. Proc Natl Acad Sci U S A (2009) 1.36
Chemoenzymatic synthesis of classical and non-classical anticoagulant heparan sulfate polysaccharides. J Biol Chem (2003) 1.23
Analysis of pharmaceutical heparins and potential contaminants using (1)H-NMR and PAGE. J Pharm Sci (2009) 1.16
High-resolution preparative separation of glycosaminoglycan oligosaccharides by polyacrylamide gel electrophoresis. Anal Biochem (2010) 1.06
Metachromatic activity of heparin and heparin fragments. Anal Biochem (1984) 1.01
Preparation and characterization of (15)N-enriched, size-defined heparan sulfate precursor oligosaccharides. Carbohydr Res (2009) 0.96
Investigating the molecular basis for the virulence of Escherichia coli K5 by nuclear magnetic resonance analysis of the capsule polysaccharide. J Mol Microbiol Biotechnol (2009) 0.90
Fondaparinux: pharmacology and clinical experience in cardiovascular medicine. Mini Rev Med Chem (2007) 0.88
Purification of the Escherichia coli K5 capsular polysaccharide and use of high-performance capillary electrophoresis to qualitative and quantitative monitor the process. Electrophoresis (2004) 0.87
The potential for circular dichroism as an additional facile and sensitive method of monitoring low-molecular-weight heparins and heparinoids. Thromb Haemost (2009) 0.85
Heparin-protein interactions. Angew Chem Int Ed Engl (2002) 7.27
Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events. Nat Biotechnol (2008) 4.46
Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members. Mol Cell Biol (2007) 3.73
Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate. J Biol Chem (2003) 2.94
Lessons learned from the contamination of heparin. Nat Prod Rep (2009) 2.81
Chemoenzymatic synthesis of homogeneous ultralow molecular weight heparins. Science (2011) 2.79
Analysis of the biochemical mechanisms for the endocrine actions of fibroblast growth factor-23. Endocrinology (2005) 2.46
The proteoglycan bikunin has a defined sequence. Nat Chem Biol (2011) 2.14
Radio-wave heating of iron oxide nanoparticles can regulate plasma glucose in mice. Science (2012) 2.14
Structural basis by which alternative splicing modulates the organizer activity of FGF8 in the brain. Genes Dev (2005) 2.10
Three-dimensional cellular microarray for high-throughput toxicology assays. Proc Natl Acad Sci U S A (2007) 2.09
Solution structures of chemoenzymatically synthesized heparin and its precursors. J Am Chem Soc (2008) 2.02
Flexible energy storage devices based on nanocomposite paper. Proc Natl Acad Sci U S A (2007) 2.02
Biochemical analysis of pathogenic ligand-dependent FGFR2 mutations suggests distinct pathophysiological mechanisms for craniofacial and limb abnormalities. Hum Mol Genet (2004) 1.92
Electron detachment dissociation of glycosaminoglycan tetrasaccharides. J Am Soc Mass Spectrom (2006) 1.89
Enzymatic redesigning of biologically active heparan sulfate. J Biol Chem (2005) 1.89
Silica nanoparticle size influences the structure and enzymatic activity of adsorbed lysozyme. Langmuir (2004) 1.86
Viral and cellular determinants of the hepatitis C virus envelope-heparan sulfate interaction. J Virol (2006) 1.71
Heparin-binding domains in vascular biology. Arterioscler Thromb Vasc Biol (2004) 1.71
Insights into the molecular basis for fibroblast growth factor receptor autoinhibition and ligand-binding promiscuity. Proc Natl Acad Sci U S A (2004) 1.70
Proline to arginine mutations in FGF receptors 1 and 3 result in Pfeiffer and Muenke craniosynostosis syndromes through enhancement of FGF binding affinity. Hum Mol Genet (2003) 1.66
E. coli K5 fermentation and the preparation of heparosan, a bioengineered heparin precursor. Biotechnol Bioeng (2010) 1.65
Chemoenzymatic design of heparan sulfate oligosaccharides. J Biol Chem (2010) 1.64
Distinguishing glucuronic from iduronic acid in glycosaminoglycan tetrasaccharides by using electron detachment dissociation. Anal Chem (2007) 1.61
High-throughput cellular microarray platforms: applications in drug discovery, toxicology and stem cell research. Trends Biotechnol (2009) 1.56
Characterization of a heparan sulfate octasaccharide that binds to herpes simplex virus type 1 glycoprotein D. J Biol Chem (2002) 1.53
Structure and function of enzymes adsorbed onto single-walled carbon nanotubes. Langmuir (2004) 1.52
Liquid chromatography/mass spectrometry sequencing approach for highly sulfated heparin-derived oligosaccharides. J Biol Chem (2003) 1.51
Inhibition of NADPH oxidase activation in endothelial cells by ortho-methoxy-substituted catechols. Endothelium (2002) 1.46
Glycomics of proteoglycan biosynthesis in murine embryonic stem cell differentiation. J Proteome Res (2007) 1.46
Ionic liquid-mediated selective extraction of lignin from wood leading to enhanced enzymatic cellulose hydrolysis. Biotechnol Bioeng (2009) 1.46
Quantification of heparan sulfate disaccharides using ion-pairing reversed-phase microflow high-performance liquid chromatography with electrospray ionization trap mass spectrometry. Anal Chem (2009) 1.45
Identification and characterization of a glycosaminoglycan recognition element of the C chemokine lymphotactin. J Biol Chem (2004) 1.42
Disaccharide analysis of glycosaminoglycan mixtures by ultra-high-performance liquid chromatography-mass spectrometry. J Chromatogr A (2011) 1.42
Structural analysis of the sulfotransferase (3-o-sulfotransferase isoform 3) involved in the biosynthesis of an entry receptor for herpes simplex virus 1. J Biol Chem (2004) 1.41
Electron detachment dissociation of dermatan sulfate oligosaccharides. J Am Soc Mass Spectrom (2007) 1.40
Influence of charge state and sodium cationization on the electron detachment dissociation and infrared multiphoton dissociation of glycosaminoglycan oligosaccharides. J Am Soc Mass Spectrom (2008) 1.40
Negative electron transfer dissociation of glycosaminoglycans. Anal Chem (2010) 1.39
Crystal structure and mutational analysis of heparan sulfate 3-O-sulfotransferase isoform 1. J Biol Chem (2004) 1.38
Toll-like receptor 4 mediates induction of the Bcl10-NFkappaB-interleukin-8 inflammatory pathway by carrageenan in human intestinal epithelial cells. J Biol Chem (2008) 1.38
Structural analysis of bikunin glycosaminoglycan. J Am Chem Soc (2008) 1.37
Orthogonal analytical approaches to detect potential contaminants in heparin. Proc Natl Acad Sci U S A (2009) 1.36
Resveratrol selectively remodels soluble oligomers and fibrils of amyloid Abeta into off-pathway conformers. J Biol Chem (2010) 1.35
Control of the heparosan N-deacetylation leads to an improved bioengineered heparin. Appl Microbiol Biotechnol (2011) 1.33
Kinetic model for FGF, FGFR, and proteoglycan signal transduction complex assembly. Biochemistry (2004) 1.33
Heparin accelerates gelsolin amyloidogenesis. Biochemistry (2006) 1.31
Room temperature ionic liquids as emerging solvents for the pretreatment of lignocellulosic biomass. Biotechnol Bioeng (2011) 1.31
Enzymatic synthesis of heparin related polysaccharides on sensor chips: rapid screening of heparin-protein interactions. Biochem Biophys Res Commun (2005) 1.29
Ultra-performance ion-pairing liquid chromatography with on-line electrospray ion trap mass spectrometry for heparin disaccharide analysis. Anal Biochem (2011) 1.28
High regeneration capacity helps tropical seeds to counter rodent predation. Oecologia (2011) 1.28
Microscale isolation and analysis of heparin from plasma using an anion-exchange spin column. Anal Biochem (2006) 1.27
Unfolding of ribonuclease A on silica nanoparticle surfaces. Nano Lett (2007) 1.26
Top-down approach for the direct characterization of low molecular weight heparins using LC-FT-MS. Anal Chem (2012) 1.26
Recent chemical and enzymatic approaches to the synthesis of glycosaminoglycan oligosaccharides. Curr Med Chem (2003) 1.25
Proteoglycomics: recent progress and future challenges. OMICS (2010) 1.25
Identification of a novel class in the alpha/beta hydrolase fold superfamily: the N-myc differentiation-related proteins. Proteins (2002) 1.25
Heparin mapping using heparin lyases and the generation of a novel low molecular weight heparin. J Med Chem (2010) 1.24
Electron-induced dissociation of glycosaminoglycan tetrasaccharides. J Am Soc Mass Spectrom (2008) 1.23
The structure of chondroitin B lyase complexed with glycosaminoglycan oligosaccharides unravels a calcium-dependent catalytic machinery. J Biol Chem (2004) 1.23
Antibiotic-resistance profile in environmental bacteria isolated from penicillin production wastewater treatment plant and the receiving river. Environ Microbiol (2009) 1.23
Three-dimensional cell culture microarray for high-throughput studies of stem cell fate. Biotechnol Bioeng (2010) 1.22
Kinetic studies on the interactions of heparin and complement proteins using surface plasmon resonance. Biochim Biophys Acta (2005) 1.22
Using a 3-O-sulfated heparin octasaccharide to inhibit the entry of herpes simplex virus type 1. Biochemistry (2008) 1.21
Aromatic small molecules remodel toxic soluble oligomers of amyloid beta through three independent pathways. J Biol Chem (2010) 1.20
Identification of the capsular polysaccharides of Type D and F Pasteurella multocida as unmodified heparin and chondroitin, respectively. Carbohydr Res (2002) 1.20
Preparation of biopolymer fibers by electrospinning from room temperature ionic liquids. Biomacromolecules (2006) 1.19
Enzyme activation for organic solvents made easy. Trends Biotechnol (2007) 1.19
Engineering of routes to heparin and related polysaccharides. Appl Microbiol Biotechnol (2011) 1.19
Structural characterization of human liver heparan sulfate. Biochim Biophys Acta (2004) 1.18